Market Overview

Generex Announces Results of Annual Stockholders' Meeting


Generex Biotechnology Corporation (OTC:GNBT) (
today announced the results of the annual meeting of the Company's
stockholders held on November 21, 2017.

Brian McGee, Dr. James H. Anderson, Jr., MD, Dr. Craig Eagle, MD, and
Dr. Gary H. Lyman, MD, MPH were elected as independent members of the
Company's Board of Directors. Joseph Moscato, the Company's President &
Chief Executive Officer, Andrew Ro, the Company's Chief Investment
Officer, Lawrence Salvo, and Kevin Centofanti were also elected to the

The proposals to: increase the authorized number of shares of the
Company's common stock; to change the name of the Company to NuGenerex
Biotechnology Holdings, Inc.; to approve the Company's 2017 equity
incentive plan; and, to ratify the appointment of MNP LLP as independent
public accountants in respect of the Company's fiscal year-end, were
each approved by the stockholders. The stockholders also voted to hold
triennial non-binding advisory votes regarding the compensation paid to
the Company's named executive officers.

A Form 8-K Current Report in respect of the specific voting results will
be filed with the U.S. Securities and Exchange Commission today.

Although Messrs. Moscato and Salvo held additional voting rights in
respect of the meeting under the terms of the shares of Series I
Convertible Preferred Stock held by them, they did not exercise those
rights and did not vote those shares at the meeting.

The Company intends to schedule an investor conference call in the
coming weeks to update stockholders on the effectuation of the Company's
business plans.

Mr. Moscato commented: "I am pleased that the holders of 80% of
the Company's outstanding shares cast votes at the meeting and that my
fellow stockholders have supported Generex management with the approval
of our reorganization initiatives and a vote of confidence in our
go-forward plans. In the coming weeks, we will host an investor
conference call to highlight Company achievements and our three-pronged
business plan encompassing: plans for current assets, being the buccal
drug delivery platform technologies, the Antigen Express
immune-therapeutic vaccines, and Hema Diagnostics; our acquisitions
strategy; and, a clinical trial and medical receivables financing

Mr. Moscato further stated: "Against all odds and many hurdles, the
determination of the Generex management team and its advisors has led to
the successful completion of the Company's reorganization plan. We now
have a clear path forward to reinvigorate our very valuable intellectual
properties and execute our other ambitious plans. I would like to
congratulate the Generex Board on the successful implementation of the
reorganization and thank them for their advice and supervision over this
past year. I would also like to welcome Kevin Centofanti, CFA, President
of highly respected merchant bank Brooks, Houghton & Company, Inc., to
the Board."

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plan," "believes,"
"will," "achieve," "anticipate," "would," "should," "subject to" or
words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts. Forward-looking statements
frequently are used in discussing potential product applications,
potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating
matters. Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known and others
of which are not. Known risks and uncertainties include those identified
from time to time in the reports filed by Generex with the Securities
and Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a guarantee
of future results or events, and one should avoid placing undue reliance
on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information,
future events or otherwise. Generex claims the protection of the safe
harbor for forward-looking statements that is contained in the Private
Securities Litigation Reform Act.

View Comments and Join the Discussion!